Go to KM Summary
ID Title Last Updated KM Node Tags
948 The stages of change model 27/03/2022
952 Principles of Preparing a realistic ACSM budget 27/03/2022
700 Sustainable Development Goals [SDGs] related to TB 04/04/2022
980 Use of Shorter Oral Bedaquiline-containing MDR/RR-TB Regimen in Pre-existing Liver Disease 07/04/2022
998 Management of DR-TB ADR: Gynecomastia 07/04/2022
997 Management of DR-TB ADR: Nephrotoxicity [Renal Toxicity] 07/04/2022
996 Management of DR-TB ADR: Seizures 07/04/2022
995 Management of DR-TB ADR: Suicidal Ideation 07/04/2022
994 Management of DR-TB ADR: Psychotic Symptoms 07/04/2022
993 Management of DR-TB ADR: Depression 07/04/2022
992 Management of DR-TB ADR: Arthralgia 07/04/2022
991 Management of DR-TB ADR: Hypothyroidism 07/04/2022
990 Management of DR-TB ADR: Hematological Abnormalities 07/04/2022
989 Management of DR-TB ADR: Giddiness 07/04/2022
274 Counselling 07/04/2022
1061 Newer Anti-TB Drugs: Delamanid [Dlm] 07/04/2022
1060 Newer Anti-TB Drugs: Bedaquiline [Bdq] 07/04/2022
1059 Newer Anti-TB Drugs 07/04/2022
1069 Shorter Oral Bedaquiline-containing MDR/RR-TB Regimen: Pre-treatment Evaluation [PTE] 07/04/2022
1063 Pre-treatment Counselling of DR-TB Patients 07/04/2022
1079 Importance of Properly Identifying Presumptive TB Cases 08/04/2022
1085 Patient Provider Support Agency [PPSA]: A Multipronged Approach to Engage the Private Sector 08/04/2022
1083 Roles of Accredited Social Health Activist [ASHA] for TB Service Delivery at ABHWCs 08/04/2022
1081 Functions of District National Health Mission 08/04/2022
1087 End TB Strategy Approach 08/04/2022
1086 Universal Access to Quality TB Care 08/04/2022
1119 Precautions to Ensure Reliability of a Test for Diagnosis of DR-TB 08/04/2022
1095 Shorter Oral Bedaquiline-containing MDR/RR-TB Regimen: Treatment Extension 08/04/2022
1096 Shorter Oral Bedaquiline-containing MDR/RR-TB Regimen: Eligibility Criteria 08/04/2022
1097 Requirements from Institutions for the Establishment of Nodal DR-TB Centre 08/04/2022